In depth
Lupus and blood tests
A positive antinuclear antibody test is the door into a lupus assessment, and it's also common in healthy people. Both of those things are true at once. The second one gets left out of almost every account you'll read of the test, which is why this page starts there.
What the research found.
The 2019 lupus classification rules start with one requirement, which is an ANA at 1 to 80 or above on HEp-2 cells. That threshold was chosen because it catches 97.8 percent of cases. The full rule set caught 96.1 percent in testing and cleared 93.4 percent.
The ANA rate in apparently healthy people fell steeply as the dilution rose, in the study most often cited for it. It was 31.7 percent at 1 to 40 and 13.3 percent at 1 to 80. It fell to 5.0 percent at 1 to 160, and to 3.3 percent at 1 to 320, which is where the familiar figure comes from.
One US survey tested a national sample at a single 1 to 80 dilution, covering everybody aged 12 and over. Of those tested, 13.8 percent came back ANA positive. Females came out at 17.8 percent and males at 9.6 percent, which is a difference that resists easy explanation.
One study assessed 263 ANA-positive patients, each of them seen by a certified rheumatologist in person rather than by a chart review. In 24 percent of those the specialist diagnosed an ANA-associated rheumatic disease. Another 26.2 percent had no sign of any disease at all, while 38.8 percent turned out to have a different rheumatology diagnosis.
One study screened 825 blood donors, of whom 15.8 percent had at least one positive antibody test. Follow-up on those donors ran for a full five years. In that time only two of the 825 went on to an autoimmune rheumatic diagnosis, which is the reassuring end of this page.
What the number means.
| Test | What it is | What a positive result means | What it doesn't mean |
|---|---|---|---|
| ANA at 1 to 80 | The screening antibody test, at the classification threshold | The entry criterion is met and the assessment continues | 13.8 percent of the US population is positive at this dilution |
| ANA at 1 to 160 | The one test again, reported at a higher dilution | Positivity in healthy people falls to 5.0 percent here | Still not a diagnosis. What else is going on decides |
| ANA at 1 to 320 | Higher dilution again | Positivity in healthy people falls to 3.3 percent | A high titer raises suspicion, it doesn't confirm anything |
| Negative ANA | No antibody detected at the reported dilution | Lupus becomes unlikely, since the entry criterion is 97.8 percent sensitive | It doesn't exclude every rheumatic disease |
| Anti-DFS70 | A specific antibody found within some ANA-positive sera | Found in 15.1 percent of archived ANA-positive sera | 93.9 percent of those had no evidence of an autoimmune rheumatic disease |
| The 2019 criteria | A classification tool, not a diagnostic test | 96.1 percent sensitivity and 93.4 percent specificity in validation | They were built to select patients for research, not to diagnose you |
A reference range is not a target. Where a range on this page differs from the one your laboratory prints, the difference is explained above and sourced below. Where no trial has tested a target, this page says so rather than offering one.
What the ANA is and what it isn't
The antinuclear antibody test looks for antibodies aimed at material inside the cell nucleus, and it's the first test sent when lupus is being considered. It's also the first requirement in the 2019 classification rules, meaning a titer of 1 to 80 or above on HEp-2 cells. That line was chosen for one reason, which is that it catches 97.8 percent of lupus cases.
Catching almost every case is just what you want in an entry test, and it comes at a price that catches people out. A test that almost everybody with the disease fails is also one a great many well people fail. Those are two sides of one property rather than a flaw in the test.
So the ANA does one job well and one job badly, which is the whole of it. A negative result makes lupus unlikely, while a positive result only means the assessment continues. By itself a positive result means very little at all.
How common a positive result is
One US survey tested at a single 1 to 80 dilution, where 13.8 percent of people aged 12 and over were ANA positive. The true value is somewhere from 12.2 to 15.5 percent, and it was more common in females than males, at 17.8 percent against 9.6 percent. That works out at roughly one person in seven.
The dilution is what makes the numbers move, and this is the single most misunderstood point about the test. In the study most often quoted, the rate in apparently healthy people fell steeply as the dilution rose. It was 31.7 percent at 1 to 40, 13.3 percent at 1 to 80, 5.0 percent at 1 to 160, and 3.3 percent at 1 to 320, and the rate didn't differ much across age groups from 20 to 60.
One claim gets repeated a great deal, which is that about 5 percent of healthy people have a positive ANA. That's right at 1 to 160 and misleading as a general claim, because many laboratories report at 1 to 80, where the healthy rate is more than twice that. So before deciding what your result means, find out which dilution it came from.
What happens to people who test positive
Two studies answer this from different directions and they agree with each other. One covered 15,357 patients sent through a single rheumatology triage system, of whom 643 were sent because of a positive ANA and 263 were assessed by a certified rheumatologist. In 24 percent of those the specialist diagnosed an ANA-associated rheumatic disease, where lupus made up 9.1 percent, Sjogren's made up another 9.1 percent, systemic sclerosis was 2.3 percent, and mixed connective tissue disease was 1.9 percent.
The other numbers from that study count for just as much. Another 26.2 percent had no sign of any disease at all, and 38.8 percent had a rheumatology diagnosis outside the ANA-associated group. So a positive ANA in somebody sent for it led to lupus about one time in eleven.
The second study looked at people who weren't sent anywhere by anybody. It screened 825 blood donors, of whom 15.8 percent had at least one positive antibody test, thirty-seven accepted a clinical assessment, and two women were diagnosed with Sjogren's disease. Follow-up ran five years, and in that time only two of the 825 got an autoimmune rheumatic diagnosis.
Anti-DFS70, worth asking about
Inside the population of positive ANA results sits a pattern with an unusually clear meaning. One study looked at stored ANA-positive samples, where 15.1 percent were anti-DFS70 positive. Of that group, 93.9 percent had no sign of an autoimmune rheumatic disease, or didn't meet the rules for one.
That makes it the most reassuring result available here, for somebody holding an unexplained positive ANA. A positive anti-DFS70 with no other autoantibodies points strongly away from the diseases the ANA was sent to find. It doesn't leave the question hanging in the way an unexplained positive does.
It isn't ordered everywhere and it isn't ordered as a matter of course. If you have a positive ANA, no symptoms that fit, and the whole thing is still nagging at you, then asking whether anti-DFS70 has been looked for is a fair and specific question. That's the kind of question that gets a useful answer at a visit.
What the classification criteria are for
The 2019 rules were built to pick matched patients for research, which is a different task from diagnosing the person in front of you. They do their own job well, catching 96.1 percent of cases in testing and clearing 93.4 percent. The 1997 rules managed 83 and 93 percent, and the 2012 set managed 97 and 84 percent.
So a rheumatologist can diagnose lupus in somebody who doesn't meet the rules, and she can decline to diagnose it in somebody who technically does. The rules are a research tool that clinicians find useful as a checklist. Treating them as a diagnostic test gives confident wrong answers in both directions at once.
That's also why the ANA doesn't need repeating once you know it. It's the door into an assessment rather than a measure of how the disease is behaving, and following a titer up and down produces worry without information. What gets followed instead is what your organs are doing.
Common misconceptions.
Myth. About 5 percent of healthy people have a positive ANA.
Reality. That figure is right at one dilution and at no other. In the study usually cited, the rate in healthy people fell as the dilution rose. It was 31.7 percent at 1 to 40, 13.3 percent at 1 to 80, 5.0 percent at 1 to 160, and 3.3 percent at 1 to 320. So the 5 percent gets quoted without the 1 to 160 attached, which makes a positive result sound far rarer than it is, and many laboratories report at 1 to 80.
Myth. A positive ANA means I probably have lupus.
Reality. One study assessed 263 ANA-positive patients, each of them seen by a rheumatologist. Of those, 24 percent had an ANA-associated rheumatic disease of any kind and lupus alone made up 9.1 percent, while 26.2 percent had no sign of any disease at all. Another study screened 825 blood donors, of whom 15.8 percent tested positive and two went on to a diagnosis over five years.
Myth. Meeting the classification criteria is how lupus is diagnosed.
Reality. The 2019 rules were built to pick matched patients for research, and they do that job well, catching 96.1 percent of cases and clearing 93.4 percent. Diagnosis is a clinical judgment, which can be made in somebody who doesn't meet the rules and withheld from somebody who does. The two questions overlap without being one question.
Myth. My ANA titer tells me how active my lupus is.
Reality. It doesn't work that way at all, and it was never meant to. The ANA is a door into a diagnosis rather than a measure of activity, and it doesn't need repeating once it's known to be positive. Disease activity gets followed with other tests, and more than that it gets followed by what your organs are doing, so chasing a titer up and down mostly causes worry.
Questions patients ask.
What does a positive ANA mean?
Less on its own than almost anyone expects. One US survey tested at a single 1 to 80 dilution and found 13.8 percent of people aged 12 and over positive, rising to 17.8 percent among females. In another study a rheumatologist saw ANA-positive patients, where 24 percent had an ANA-associated rheumatic disease and 26.2 percent had no sign of any disease, so the result opens a question rather than answering one.
Why do different sources give different rates in healthy people?
Because the rate depends on the dilution reported, and most sources don't say which one they mean. In the study most often cited, the rate in apparently healthy people fell as the dilution rose. It was 31.7 percent at 1 to 40, 13.3 percent at 1 to 80, 5.0 percent at 1 to 160, and 3.3 percent at 1 to 320. The 5 percent figure people quote is right at 1 to 160 and wrong as a general claim.
Does a negative ANA rule out lupus?
It makes lupus unlikely, which is different from impossible, and it's the closest thing to an all-clear this page has. The 2019 rules start with an ANA at 1 to 80 or above, and that threshold was picked because it catches 97.8 percent of cases. So somebody with a negative ANA and no other features is being checked for something else.
What is anti-DFS70 and why does it count?
It's a specific antibody found inside some positive ANA results, and it's the most reassuring thing on this page. One study looked at stored ANA-positive samples, where 15.1 percent were anti-DFS70 positive, and 93.9 percent of that group had no sign of disease or didn't meet the rules for one. So it's worth asking whether it was looked for in your case.
What are the classification criteria for?
Picking matched patients for research, rather than diagnosing any one person. In testing, the 2019 rules caught 96.1 percent of cases and cleared 93.4 percent, while the older 1997 rules managed 83 and 93 percent and the 2012 set managed 97 and 84 percent. Those are good numbers for their purpose, and a rheumatologist can still diagnose lupus in somebody who doesn't meet them.
Should my ANA be repeated to follow my disease?
Generally not, because it's a test for diagnosis rather than a measure of activity. Once a positive result is known, repeating it tells you very little about how the disease is behaving, and watching a titer move causes worry rather than news. What gets judged instead is what your organs are doing, with other tests alongside that, and your rheumatologist picks those.
I'm ANA positive and feel fine. What happens now?
The most useful data on that comes from blood donors. One study screened 825 of them, where 15.8 percent had at least one positive antibody test, thirty-seven accepted a clinical assessment, and two women were diagnosed with Sjogren's disease. Follow-up ran five years, and in that time only two of the 825 got an autoimmune rheumatic diagnosis, so most positive results in well people stay just that.
References.
- Aringer M; Costenbader K; Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2019;71:1400-1412. 10.1002/art.40930Multiphase classification criteria development with derivation
- Tan EM; Feltkamp TE; Smolen JS et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis and rheumatism. 1997;40:1601-11. 10.1002/art.1780400909Multicentre cross-sectional study of a putatively normal population across 15 international laboratories
- Satoh M; Chan E; Ho L et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis & Rheumatism. 2012;64:2319-2327. 10.1002/art.34380Cross-sectional analysis of a nationally representative population survey
- Andraos R; Ahmad A; Wirestam L et al. Screening for autoimmune diseases in apparently healthy antinuclear antibody positive individuals. Frontiers in Medicine. 2024;11. 10.3389/fmed.2024.1455673Prospective screening study of 825 consecutive apparently healthy blood donors with structured questionnaire
- Fitch-Rogalsky C; Steber W; Mahler M et al. Clinical and Serological Features of Patients Referred through a Rheumatology Triage System because of Positive Antinuclear Antibodies. PLoS ONE. 2014;9:e93812. 10.1371/journal.pone.0093812Cross-sectional retrospective analysis of a central rheumatology triage database
- Quevedo-Abeledo J; Sánchez-Pérez H; Tejera-Segura B et al. Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. The Journal of Rheumatology. 2020;48:339-347. 10.3899/jrheum.200435Cross-sectional study of 413 subjects
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.
Across the site